In regards to your statement (quote): "My opinio
Post# of 36536
"My opinion is that we will be stuck here until revenue starts being generated ... or at least a guarantee of revenue ..."
I am sure that a statement on ...
a) GNBT/NGIO having received $50+ Million from the chinese partners
b) further details about commencement of clinical trials in the US, as well as China, and related timelines.
c) concrete details about the NGIO IPO including the info on the date and initial share price
d) further details on the therapeutic side of things just barely mentioned at the end of yesterday's PR
e) ...
should have the power to significantly drive the share price north.
In addition, I cannot agree with the quote from Bill Parcell, as this is false in so many occasions. No matter if a share price is manipulated downwards, as in the GNBT case here, or manipulated upwards, or even artifically inflated due to a short squeeze, as recently happened with the GME share price. As long as we are not talking "blue chip" stocks, the current share price does extremely often NOT reflect the fair valuation of a company. So on the OTC in particular, a company is very likely significantly something else than the stock price says. The only truth really is a CEO, such as Joe Moscato, needs to deal and live with the truth of the current pps, which I am sure can be extemely frustrating at times, especially when the PPS so obviously is undervalued.